Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Solid Tumors
Filter by Topic
Bladder Cancer
Breast Cancer
Colon Cancer
Colorectal Cancer
Gastric Cancer
Genitourinary Cancers
GI Cancers
Gynecologic Cancer
Head and Neck Cancer
Liver Cancer
Lung Cancer
Melanoma
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Thyroid Cancer
Nivolumab plus Ipilimumab Combination Improves Survival in Patients with Metastatic NSCLC
Lung Cancer
,
Personalized Medicine
,
Solid Tumors
December 2019, Vol 10, No 6
Barcelona, Spain—The immunotherapy combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) improved overall survival (OS) compared with chemotherapy as first-line treatment in patients with advanced non–small-cell lung cancer (NSCLC) and PD-L1 expression ≥1%, according to results of CheckMate 227.
Read Article
Osimertinib Superior TKI as First-Line Treatment of Advanced NSCLC with EGFR Mutation
By
Phoebe Starr
Lung Cancer
,
Personalized Medicine
,
Solid Tumors
December 2019, Vol 10, No 6
Barcelona, Spain—Osimertinib (Tagrisso), a third-generation EGFR tyrosine kinase inhibitor (TKI), extended overall survival (OS) compared with older TKI EGFR inhibitors, including gefitinib (Iressa) or erlotinib (Tarceva), as first-line treatment for patients with advanced non–small-cell lung cancer (NSCLC) and
EGFR
mutation in the phase 3 clinical trial called FLAURA.
Read Article
October 28, 2019 – Oncology News & Updates
FDA Approvals, News & Updates
,
In the News
,
Ovarian Cancer
,
Solid Tumors
Web Exclusives
Read Article
Pembrolizumab as a First-Line Standard-of-Care Option in Advanced Non–Small-Cell Lung Cancer
By
Wayne Kuznar
Lung Cancer
,
Solid Tumors
,
Personalized Medicine
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Read Article
With Access to Care, Black Men in the United States Have Same Prostate Cancer Outcomes as White Men
By
Phoebe Starr
Prostate Cancer
,
Solid Tumors
,
Personalized Medicine
August 2018, Vol 9, No 2 | Payers’ Perspectives In Oncology: ASCO
Read Article
Long-Term Data Confirm Survival Benefit for Pembrolizumab in Advanced NSCLC
By
Phoebe Starr
Lung Cancer
,
Solid Tumors
,
Personalized Medicine
October 2019, Vol 10, No 5
Chicago, IL—Treatment with the immune checkpoint inhibitor pembrolizumab (Keytruda) dramatically improved 5-year survival for patients with advanced non–small-cell lung cancer (NSCLC) compared with expected survival in the preimmunotherapy era, according to the 5-year follow-up data from the phase 1b KEYNOTE-001 clinical trial. The study was presented at ASCO 2019 and was published simultaneously in the
Journal of Clinical Oncology
.
Read Article
New Compounds Hold Promise for Prostate Cancer
Prostate Cancer
,
Solid Tumors
September 2010, Vol 1, No 4
Virtually all patients that succumb to prostate cancer die of metastatic castration-resistant disease (CRPC). Docetaxel, the standard of care for these patients, provides a modest prolongation of survival, but there is an urgent need for novel treatment strategies.
Read Article
MONALEESA-7 Sets New Standard of Care for Premenopausal Advanced Breast Cancer: Adding CDK4/6 to Endocrine Therapy Extends Survival
By
Phoebe Starr
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO
Chicago, IL—The addition of the cyclin-dependent kinase (CDK)4/CDK6 inhibitor ribociclib (Kisqali) to standard endocrine therapy significantly extended overall survival (OS) compared with endocrine therapy alone in premenopausal women with hormone receptor (HR)-positive,
HER2
-negative advanced breast cancer, according to results of the phase 3 MONALEESA-7 clinical trial presented at ASCO 2019.
Read Article
BLU-667, Selective RET Inhibitor, Demonstrates Antitumor Activity in NSCLC with RET Fusion
By
Wayne Kuznar
Lung Cancer
,
Solid Tumors
,
Personalized Medicine
August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO
Chicago, IL—BLU-667, a novel inhibitor of RET, elicited responses in more than 50% of patients with
RET
fusion–positive advanced non–small-cell lung cancer (NSCLC), according to data from an ongoing phase 1 clinical trial presented at ASCO 2019.
Read Article
Repotrectinib, an Investigational TKI, Elicits Responses in Patients with Advanced NSCLC and ROS1 Alterations
By
Wayne Kuznar
Lung Cancer
,
Solid Tumors
,
Personalized Medicine
August 2019, Vol 10, No 4 | Payers’ Perspectives In Oncology: ASCO
Chicago, IL—Expanded data from an early phase 1/2 clinical trial showed that treatment with repotrectinib, an investigational tyrosine kinase inhibitor (TKI) with potent selectivity against tumors with
ROS1
rearrangement, induced a response in 9 of 11 patients with TKI-naïve, advanced non–small-cell lung cancer (NSCLC) and
ROS1
fusion.
Read Article
Page 1 of 16
1
2
3
4
5
6
7
8
9
10
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Perioperative Nivolumab Extends Event-Free Survival in Resectable NSCLC
William King
2.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
3.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma